ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO587

Serum Sulfatide Level as a Marker for Differentiation and Activity Assessment in Renal Vasculitis Diseases

Session Information

Category: Glomerular Diseases

  • 1302 Glomerular Diseases: Immunology and Inflammation

Authors

  • Aomura, Daiki, Shinshu Daigaku Igakubu Fuzoku Byoin, Matsumoto, Nagano, Japan
  • Harada, Makoto, Shinshu Daigaku Igakubu Fuzoku Byoin, Matsumoto, Nagano, Japan
  • Nimura, Takayuki, Shinshu Daigaku Igakubu Fuzoku Byoin, Matsumoto, Nagano, Japan
  • Yamada, Yosuke, Shinshu Daigaku Igakubu Fuzoku Byoin, Matsumoto, Nagano, Japan
  • Hashimoto, Koji, Shinshu Daigaku Igakubu Fuzoku Byoin, Matsumoto, Nagano, Japan
  • Kamijo, Yuji, Shinshu Daigaku Igakubu Fuzoku Byoin, Matsumoto, Nagano, Japan

Group or Team Name

  • Department of Nephrology at Shinshu University school of medicine
Background

Sulfatides are glycosphingolipids associated with coagulation and platelet aggregation, suggesting a possible involvement in renal vasculitis (RV). However, research on this notion is extremely limited, with only one study on a small population of healthy individuals and patients with ANCA-associated vasculitis (AAV) revealing serum sulfatide (SS) level as a possible differentiation marker in AAV, especially with active crescentic findings on kidney biopsy. To further assess the association between SS and RV, we performed a retrospective study with a larger sample size including several RV diseases.

Methods

This cross-sectional investigation included patients admitted to the Nephrology Department of Shinshu University Hospital (Japan) after April 2008. Patients who were firstly diagnosed as having IgA vasculitis (IgAV), AAV, or anti-GBM disease (GBM) were included. As controls, donor candidates for living kidney transplantation (donors) were analyzed as well. SS levels were analyzed using stored frozen serum samples.

Results

The mean±standard deviation SS levels of donors (n=23), IgAV (n=26), AAV (n=64), and GBM (n=10) were 8.30±1.68, 6.14±1.59, 5.30±2.02, and 2.72±0.94 nmol/mL, respectively. Regarding associations with kidney biopsy findings, SS levels were significantly higher in patients with a higher crescentic score (Oxford classification) in IgAV. In contrast, SS levels were significantly lower in patients with a crescent-type phenotype (Berden classification) in AAV and negatively correlated with the percentage of glomeruli with cellular crescents in GBM (r=-0.76, p=0.02). Those associations of active pathological findings with SS level were stronger than with other possible markers including serum C-reactive protein level in all RV groups.

Conclusion

SS level is a possible marker for differentiation and activity assessment in RV diseases.